On GLP-1 medications, your body needs more support
For GLP-1 drugs, the risks include: Increased anxiety or panic from unstable blood sugar Triggering or worsening depression Heightened risk of obsessive eating behaviors Potential for self-esteem issues or body image dysmorphia For someone already struggling with mental health, these risks are compounded making proper medical oversight essential
GLP-1 Agonists Market size was valued at US$ 37,113.2 billion in 2025 and is expected to reach US$ 118,926.1 billion by 2032, growing at a significant CAGR of 18.1% from 2026-2032
These conditions require standard doses for effective management
Understanding how these sweeteners affect GLP-1, CCK, PYY, and ghrelin secretion can provide insights into their potential benefits for weight management and metabolic health 2